No­vo Nordisk boasts $14.6B in H1 obe­si­ty, di­a­betes sales, but ques­tions linger on broad­er cov­er­age

No­vo Nordisk’s sales from its obe­si­ty and di­a­betes care prod­ucts in­creased by 36% to $14.6 bil­lion (99 bil­lion Dan­ish kro­ner) in the first half of this year, dri­ven main­ly by its GLP-1s like semaglu­tide, which just read out car­dio­vas­cu­lar da­ta in the SE­LECT tri­al in obese pa­tients.

No­vo’s strong first-half earn­ings are a sign that the pop­u­lar­i­ty around GLP-1 med­ica­tions is still on­ly just start­ing to heat up, and it’s go­ing to lead to more man­u­fac­tur­ing pres­sure while dis­cus­sions evolve around how the med­ica­tions are paid for.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER